Author: webcomm

The CCHI IOFM Core funded ten applications submitted in response to our RFA released August 26, 2019.  The CCHI Steering Committee sought applications from CCHI centers to capitalize on emerging opportunities and encourage multi-center, multi-disciplinary collaborations. The immediate objective of the CCHI is to support mechanistic and hypothesis-testing studies to understand human immunity applicable to the biodefense effort (i.e. innate, adaptive and mucosal immune responses to infection, vaccination and adjuvants). Studies on immune-mediated diseases (e.g. airway allergy, food allergy, autoimmunity, organ transplant rejection) are also of interest, as these data will provide a more comprehensive understanding of the human immune system.

Stephanie Boisson-Dupuis, PhD from Rockefeller University applied from the Rockefeller University CCHI U19 Center (Ravetch, PD/PI).  Project is entitled “Inherited human PD-1 deficiency”

Stylianos Bournazos, PhD from Rockefeller University applied from the Rockefeller University CCHI U19 Center (Ravetch, PD/PI).  Project is entitled “Modulating the antibody response to vaccination through targeting the CD40 axis”

The Cooperative Centers on Human Immunology (CCHI) were awarded in response to RFA-AI-17-040 to support studies that will advance our understanding of the mechanisms regulating human immune response.  The CCHI U19 mechanism supports mechanistic and hypothesis-testing studies to understand human immunity applicable to the biodefense effort; i.e. innate, adaptive and mucosal immune responses to infection, vaccination and adjuvants. Studies on immune-mediated diseases (e.g. airway allergy, food allergy, autoimmunity, organ transplant rejection) are also of interest, as these data will provide a more comprehensive understanding of the human immune system.

The program supports the centralized infrastructure needed to promote and coordinate multi-disciplinary research in human immunology. Additional objectives are to promote public access to CCHI-supported data and metadata through public portals such as ImmPort, and develop new technologies to support human immunology research.